Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of management would be participating in the upcoming BofA Securities Healthcare Conference 2024, which will be held on May 14-15, 2024 in Las Vegas, NV.
Members of Alvotech’s management team will be attending the conference and hosting one-on-one meetings with investors.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, Senior Director
alvotech.ir@alvotech.com
FOR MORE INFORMATION
Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, X and YouTube.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Erste Bank Hungary launches Flight Delay Insurance, a new service available to its customers in the George app, powered by leading insurtech Companjon17.5.2024 08:30:00 CEST | Press release
The innovative insurance solution offers Erste customers protection of their travel plans from departure delays. Companjon automatically monitors the covered flight’s status and triggers a claim for HUF 16,000 compensation – instantly credited to the customer’s account – when the delay reaches one hour. DUBLIN, Ireland, May 17, 2024 (GLOBE NEWSWIRE) -- Erste Bank Hungary, part of Erste Group, one of the largest financial services providers in Central and Eastern Europe, has launched Erste Flight Delay Insurance to its banking customers in their George app. Available from today, George’s newest digital service enables retail forint account holders to protect their travel plans against flight departure delays of one hour. The insurance is powered by leading European B2B2C insurtech Companjon, which specializes in fully digital, AI-driven embedded insurance solutions. The Erste Flight Delay Insurance is a completely automated experience for Erste customers: on the day of flight departure,
Effnetplattformen Holding AB (publ): Delårsrapport Januari - mars 202417.5.2024 08:30:00 CEST | Pressemelding
Stockholm, 17 maj 2024 -- Effnetplattformen Holding AB (publ) DELÅRSRAPPORT Januari - mars 2024 Koncernens omsättning för perioden januari – mars 2024 uppgick till KSEK 1 234 (4 456) eller SEK 0,09 (0,33) per aktie. Rörelseresultatet för perioden uppgick till KSEK -2 221 (1 189). Nettoresultatet för perioden var KSEK -2 667 (942) eller SEK -0,20 (0,07) per aktie. Kassaflödet från den löpande verksamheten för perioden uppgick till KSEK -2 658 (-112) eller SEK -0,20 (-0,01) per aktie. Koncernens likvida medel uppgick vid periodens slut till KSEK 21 976 (vid årets början 24 669) vilket motsvarar SEK 1,62 (vid årets början 1,82) per aktie. Koncernens finansiella anläggningstillgångars bokförda värde uppgick vid periodens slut till KSEK 3 562 (vid årets början 4 577) vilket motsvarar SEK 0,26 (vid årets början 0,34) per aktie. Marknadsvärdet uppgick till KSEK 3 562 (vid årets början 4 577). Det egna kapitalet uppgick vid periodens utgång till KSEK 24 728 (vid årets början 27 395) eller SEK
Suspended trading due to national holiday17.5.2024 08:01:00 CEST | Press release
Lysaker, 17 May 2024 The below funds are suspended from the live trading on Nasdaq Copenhagen for Friday 17th May due to national holiday in Norway. As noted in the Financial Calender, the funds may not be available for trading on 1st May and 17th May due to official holidays affecting the Management Company's staffing. The share classes will resume trading on Tuesday 21st May. Regards Storebrand Asset Management AS Contacts: Kim Toftegaard Andreassen, Director, Kim.Toftegaard.Andreassen@storebrand.com Frode Aasen, Product Manager, fdc@storebrand.com Fund name and share classSymbolISINSKAGEN Focus ASKIFOANO0010735129SKAGEN Global ASKIGLONO0008004009SKAGEN Kon-Tiki ASKIKONNO0010140502SKAGEN m2 ASKIM2NO0010657356SKAGEN Vekst ASKIVEKNO0008000445Storebrand Indeks – Alle Markeder A5STIIAMNO0010841588Storebrand Indeks – Nye Markeder A5STIINMNO0010841570Storebrand Global ESG Plus A5STIGEPNO0010841604Storebrand Global Solutions A5STIGSNO0010841612Storebrand Global Multifactor A5STIGMNO00108415
QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency17.5.2024 08:00:00 CEST | Press release
STOCKHOLM, Sweden, May 17, 2024 (GLOBE NEWSWIRE) -- QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality Control Laboratories issued by the Swedish Medical Products Agency (Läkemedelsverket). QuTEM is thereby authorized to perform critical quality control analysis essential for the release of medicines to the market. The GMP Certificates and Manufacturing Permits cover medicinal and investigational medicinal products for both human and veterinary use. GMP regulations are formal standards established by regulatory bodies worldwide to ensure the quality, safety, and efficacy of pharmaceutical products. Manufacturing Permits for Independent Quality Control Laboratories are granted by the Swedish regulatory authority since January 2024 to laboratories that conduct tests directly impacting the releas
Teckningskurs för nyttjande av teckningsoptioner av serie TO7 i Terranet AB har fastställts till 0,073 SEK per aktie av serie B. Teckningsperioden inleds på måndag, den 20 maj 2024.17.5.2024 08:00:00 CEST | Pressemelding
Terranet AB (publ) (”Terranet” eller ”Bolaget”) emitterade 182 664 660 teckningsoptioner av serie TO7 i samband med Bolagets företrädesemission under det andra kvartalet 2023. Varje teckningsoption ger rätt att teckna en (1) ny B-aktie i Bolaget. Teckningskursen för teckningsoptionerna av serie TO7 ska fastställas till 70 procent av den volymvägda genomsnittskursen i Bolagets aktie på Nasdaq First North Premier Growth Market under mätperioden från och med den 2 maj 2024 till och med den 16 maj 2024, dock inte lägre än kvotvärdet för Bolagets aktier och inte högre än 0,27 SEK per aktie. Den volymvägda genomsnittskursen i Bolagets aktie uppgick under mätperioden till 0,104 SEK och således har teckningskursen fastställts till 0,073 SEK. Investerat belopp avrundas uppåt till två decimaler. Teckning av aktier med stöd av teckningsoptioner av serie TO7 pågår från och med den 20 maj 2024 till och med den 3 juni 2024. Fullständiga villkor för teckningsoptionerna finns att tillgå på Bolagets we